4/A: Structure Therapeutics CEO Corrects Stock Option Exercise Price in Amended SEC Filing

Raymond C. Stevens, CEO of Structure Therapeutics, filed an amendment to a Form 4, correcting the exercise price of stock options to reflect the price of Ordinary Shares rather than American Depositary Shares (ADSs).

Summary

• Raymond C. Stevens, the CEO of Structure Therapeutics Inc., filed an amended Form 4 with the SEC on March 20, 2024.
• The amendment corrects the exercise price of a stock option granted on March 15, 2024.
• The original filing incorrectly stated the exercise price as that of the American Depositary Shares (ADSs), while the corrected filing clarifies that the exercise price is based on the fair market value per Ordinary Share.
• The stock option allows Stevens to buy 335,481 Ordinary Shares at an exercise price of $11.75 per share.
• 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
• The option was granted on March 15, 2024, and expires on March 14, 2034.
• Each ADS represents three Ordinary Shares of the Issuer.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the stock option exercise price ensures accurate reporting to shareholders and the public.

Key Dates